Literature DB >> 11023702

New aspects on the melanocortins and their receptors.

J E Wikberg1, R Muceniece, I Mandrika, P Prusis, J Lindblom, C Post, A Skottner.   

Abstract

Knowledge of melanocortins and their receptors has increased tremendously over the last few years. The cloning of five melanocortin receptors, and the discovery of two endogenous antagonists for these receptors, agouti and agouti-related peptide, have sparked intense interest in the field. Here we give a comprehensive review of the pharmacology, physiology and molecular biology of the melanocortins and their receptors. In particular, we review the roles of the melanocortins in the immune system, behaviour, feeding, the cardiovascular system and melanoma. Moreover, evidence is discussed suggesting that while many of the actions of the melanocortins are mediated via melanocortin receptors, some appear to be mediated via mechanisms distinct from melanocortin receptors. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11023702     DOI: 10.1006/phrs.2000.0725

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  46 in total

1.  MC(1) receptors are constitutively expressed on leucocyte subpopulations with antigen presenting and cytotoxic functions.

Authors:  G Neumann Andersen; O Nagaeva; I Mandrika; R Petrovska; R Muceniece; L Mincheva-Nilsson; J E Wikberg
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

2.  Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists.

Authors:  Irina D Pogozheva; Biao-Xin Chai; Andrei L Lomize; Tung M Fong; David H Weinberg; Ravi P Nargund; Michael W Mulholland; Ira Gantz; Henry I Mosberg
Journal:  Biochemistry       Date:  2005-08-30       Impact factor: 3.162

3.  Melanocortins protect against multiple organ dysfunction syndrome in mice.

Authors:  Alessandra Bitto; Francesca Polito; Domenica Altavilla; Natasha Irrera; Daniela Giuliani; Alessandra Ottani; Letteria Minutoli; Luca Spaccapelo; Maria Galantucci; Renzo Lodi; Giuseppe Guzzo; Salvatore Guarini; Francesco Squadrito
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

Review 4.  Melanocortinergic control of penile erection.

Authors:  H Wessells; J E Blevins; T W Vanderah
Journal:  Peptides       Date:  2005-10       Impact factor: 3.750

5.  Effect of Semax on changes in pain sensitivity and behavior of animals induced by forced swimming.

Authors:  D M Ivanova; D A Vilenskiĭ; N G Levitskaya; L A Andreeva; L Yu Alfeeva; A A Kamenskiĭ; N F Miasoedov
Journal:  Dokl Biol Sci       Date:  2006 Mar-Apr

6.  HS014, a selective melanocortin-4 (MC4) receptor antagonist, modulates the behavioral effects of morphine in mice.

Authors:  N Eser Ercil; Ruggero Galici; Robert A Kesterson
Journal:  Psychopharmacology (Berl)       Date:  2005-02-18       Impact factor: 4.530

7.  Autoantibodies against alpha -MSH, ACTH, and LHRH in anorexia and bulimia nervosa patients.

Authors:  Sergueï O Fetissov; Jarmila Hallman; Lars Oreland; Britt Af Klinteberg; Eva Grenbäck; Anna-Lena Hulting; Tomas Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-16       Impact factor: 11.205

Review 8.  Malignant melanoma and melanocortin 1 receptor.

Authors:  A A Rosenkranz; T A Slastnikova; M O Durymanov; A S Sobolev
Journal:  Biochemistry (Mosc)       Date:  2013-11       Impact factor: 2.487

9.  The neuropeptide alpha-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans.

Authors:  Karin Loser; Thomas Brzoska; Vinzenz Oji; Matteo Auriemma; Maik Voskort; Verena Kupas; Lars Klenner; Cornelius Mensing; Axel Hauschild; Stefan Beissert; Thomas A Luger
Journal:  PLoS One       Date:  2010-02-01       Impact factor: 3.240

10.  Local treatment with alpha-melanocyte stimulating hormone reduces corneal allorejection.

Authors:  Pedram Hamrah; Zdenka Haskova; Andrew W Taylor; Qiang Zhang; Bruce R Ksander; M Reza Dana
Journal:  Transplantation       Date:  2009-07-27       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.